Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT03386357 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

115

Enrollment

OTHER

Sponsor class

Stopped slow recruitment

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

COMBINATION_PRODUCT: A (pembrolizumab+RT)
DRUG: B (pembrolizumab)

Sponsor

University of Erlangen-Nürnberg Medical School